Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasmine Foo

Showing results (11-20 of 44) with videos related to

Pageof 5
Sort By:
Evolutionary Applications|February 12, 2013
Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumorsJasmine Foo, Kevin Leder, Shannon M Mumenthaler
Journal of Theoretical Biology|April 17, 2014
Multifocality and recurrence risk: a quantitative model of field cancerizationJasmine Foo, Kevin Leder, Marc D Ryser
Journal of Theoretical Biology|April 22, 2023
Statistical inference of the rates of cell proliferation and phenotypic switching in cancerEinar Bjarki Gunnarsson, Jasmine Foo, Kevin Leder
NPJ Systems Biology and Applications|August 24, 2025
Optimal dosing of anti-cancer treatment under drug-induced plasticityEinar Bjarki Gunnarsson, Benedikt Vilji Magnússon, Jasmine Foo
Biorxiv : the Preprint Server for Biology|July 15, 2024
Early ctDNA kinetics as a dynamic biomarker of cancer treatment responseAaron Li, Emil Lou, Kevin Leder, et al.
JCO Clinical Cancer Informatics|March 7, 2025
Early Circulating Tumor DNA Kinetics as a Dynamic Biomarker of Cancer Treatment ResponseAaron Li, Emil Lou, Kevin Leder, et al.
Cell Reports|May 6, 2014
Patterns of somatically acquired amplifications and deletions in apparently normal tissues of ovarian cancer patientsLeila Aghili, Jasmine Foo, James DeGregori, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancerJasmine Foo, Juliann Chmielecki, William Pao, et al.
Journal of Theoretical Biology|January 19, 2020
Understanding the role of phenotypic switching in cancer drug resistanceEinar Bjarki Gunnarsson, Subhajyoti De, Kevin Leder, et al.
NPJ Systems Biology and Applications|August 6, 2025
A statistical framework for detecting therapy-induced resistance from drug screensChenyu Wu, Einar Bjarki Gunnarsson, Jasmine Foo, et al.
Pageof 5

Showing results (11-20 of 44) with videos related to

Sort By:
Pageof 5
Evolutionary Applications|February 12, 2013
Cancer as a moving target: understanding the composition and rebound growth kinetics of recurrent tumorsJasmine Foo, Kevin Leder, Shannon M Mumenthaler
Journal of Theoretical Biology|April 17, 2014
Multifocality and recurrence risk: a quantitative model of field cancerizationJasmine Foo, Kevin Leder, Marc D Ryser
Journal of Theoretical Biology|April 22, 2023
Statistical inference of the rates of cell proliferation and phenotypic switching in cancerEinar Bjarki Gunnarsson, Jasmine Foo, Kevin Leder
NPJ Systems Biology and Applications|August 24, 2025
Optimal dosing of anti-cancer treatment under drug-induced plasticityEinar Bjarki Gunnarsson, Benedikt Vilji Magnússon, Jasmine Foo
Biorxiv : the Preprint Server for Biology|July 15, 2024
Early ctDNA kinetics as a dynamic biomarker of cancer treatment responseAaron Li, Emil Lou, Kevin Leder, et al.
JCO Clinical Cancer Informatics|March 7, 2025
Early Circulating Tumor DNA Kinetics as a Dynamic Biomarker of Cancer Treatment ResponseAaron Li, Emil Lou, Kevin Leder, et al.
Cell Reports|May 6, 2014
Patterns of somatically acquired amplifications and deletions in apparently normal tissues of ovarian cancer patientsLeila Aghili, Jasmine Foo, James DeGregori, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 18, 2012
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancerJasmine Foo, Juliann Chmielecki, William Pao, et al.
Journal of Theoretical Biology|January 19, 2020
Understanding the role of phenotypic switching in cancer drug resistanceEinar Bjarki Gunnarsson, Subhajyoti De, Kevin Leder, et al.
NPJ Systems Biology and Applications|August 6, 2025
A statistical framework for detecting therapy-induced resistance from drug screensChenyu Wu, Einar Bjarki Gunnarsson, Jasmine Foo, et al.
Pageof 5